AGRX - Agile Therapeutics Inc Stock Price, Fair Value and News

0.38USD-0.02 (-5.00%)Delayed

Market Summary

USD0.38-0.02

Delayed

-5.00%

AGRX Stock Price

View Fullscreen

AGRX RSI Chart

AGRX Valuation

Market Cap

2.5M

Price/Earnings (Trailing)

-0.32

Price/Sales (Trailing)

0.12

EV/EBITDA

-0.21

Price/Free Cashflow

-0.24

AGRX Price/Sales (Trailing)

AGRX Profitability

Operating Margin

59.74%

EBT Margin

-36.25%

Return on Equity

75.48%

Return on Assets

-61.8%

Free Cashflow Yield

-421.57%

AGRX Fundamentals

AGRX Revenue

Revenue (TTM)

21.5M

Rev. Growth (Yr)

49.91%

Rev. Growth (Qtr)

58.14%

AGRX Earnings

Earnings (TTM)

-7.8M

Earnings Growth (Yr)

123.83%

Earnings Growth (Qtr)

128.73%

Breaking Down AGRX Revenue

Last 30 days

2.7%

Last 90 days

-68.3%

Trailing 12 Months

-90.9%

How does AGRX drawdown profile look like?

AGRX Financial Health

Current Ratio

0.56

Debt/Equity

-0.15

Debt/Cashflow

-6.9

AGRX Investor Care

Buy Backs (1Y)

85.29%

Diluted EPS (TTM)

-2.04

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	21.5M	0	0	0
2023	12.9M	16.3M	20.0M	19.6M
2022	5.7M	6.7M	8.4M	10.9M
2021	1.6M	2.5M	3.3M	4.1M
2020	0	0	0	749.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Agile Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Oct 03, 2023	coiante scott m	acquired	-	-	20,000	chief financial officer
Jun 28, 2023	gilmore geoffrey	acquired	-	-	20,216	chief administrative officer
Jun 28, 2023	welsh amy	acquired	-	-	13,500	chief commercial officer
Jun 28, 2023	altomari alfred	acquired	-	-	46,463	chief executive officer
Jun 28, 2023	conway robert g	acquired	-	-	13,500	chief supply chain officer
Jun 28, 2023	korner paul	acquired	-	-	13,500	chief medical officer
Jun 08, 2023	fischer seth h. z.	acquired	-	-	935	-
Jun 08, 2023	torrente josephine	acquired	-	-	935	-
Jun 08, 2023	hubbard john w	acquired	-	-	935	-
Jun 08, 2023	carson sandra	acquired	-	-	935	-

Which funds bought or sold AGRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	COMERICA BANK	sold off	-100	-8.00	-	-%
May 15, 2024	STATE STREET CORP	sold off	-100	-21,144	-	-%
May 15, 2024	MORGAN STANLEY	sold off	-100	-88.00	-	-%
May 15, 2024	INVESTOR AB	unchanged	-	-2,824	596	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	sold off	-100	-210,600	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	sold off	-100	-6,388	-	-%
May 15, 2024	Royal Bank of Canada	sold off	-100	-2,000	-	-%
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-37,532	-	-%
May 13, 2024	UBS Group AG	sold off	-100	-2,705	-	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	sold off	-100	-26,808	-	-%

Are Funds Buying or Selling AGRX?

Are funds buying AGRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AGRX

No. of Funds

Unveiling Agile Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	lind global fund ii lp	1.8%	44,750	SC 13G/A
Feb 06, 2024	intracoastal capital, llc	0.9%	23,961	SC 13G/A
Feb 14, 2023	perceptive advisors llc	0%	0	SC 13G/A
Feb 13, 2023	lind global fund ii lp	9.9%	4,459,759	SC 13G/A
Feb 08, 2023	intracoastal capital, llc	6.3%	2,730,000	SC 13G/A
Jul 12, 2022	lind global fund ii lp	9.9%	3,250,223	SC 13G
Jul 11, 2022	intracoastal capital, llc	9.99%	3,430,345	SC 13G
Feb 14, 2022	perceptive advisors llc	17.5%	21,294,485	SC 13G/A
Feb 09, 2022	vanguard group inc	3.70%	4,494,704	SC 13G/A
Jul 12, 2021	blackrock inc.	1.5%	1,308,650	SC 13G/A

Recent SEC filings of Agile Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	8-K	Current Report
May 15, 2024	10-Q	Quarterly Report
Apr 29, 2024	10-K/A	Annual Report
Apr 09, 2024	8-K	Current Report
Mar 28, 2024	8-K	Current Report
Mar 28, 2024	10-K	Annual Report
Mar 25, 2024	8-K	Current Report
Mar 14, 2024	8-K	Current Report
Feb 23, 2024	8-K	Current Report
Feb 23, 2024	424B5	Prospectus Filed

Peers (Alternatives to Agile Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	372.2B	85.6B	6.82%	-1.69%	9.67	4.35	5.68%	202.39%
MRK	332.3B	61.4B	4.65%	15.09%	144.1	5.41	6.11%	-82.30%
AMGN	167.7B	29.5B	18.35%	39.38%	44.55	5.68	12.76%	-52.47%
PFE	162.3B	57.8B	12.71%	-21.46%	129.52	2.81	76.51%	-86.81%
GILD	84.4B	27.4B	1.23%	-13.37%	174.21	3.07	1.51%	-91.32%
TEVA	18.4B	16.0B	23.52%	97.09%	-37.29	1.15	7.23%	71.10%
MID-CAP
ALKS	4.1B	1.7B	0.67%	-19.91%	9.41	2.37	54.01%	364.56%
PRGO	4.1B	4.6B	-0.70%	-10.77%	-528.11	0.89	-0.06%	94.55%
BHC	2.5B	9.0B	-21.94%	-21.03%	-5.45	0.28	10.01%	-27.45%
AMPH	2.1B	676.2M	8.56%	-0.82%	13.75	3.14	30.38%	66.04%
SMALL-CAP
TLRY	1.5B	743.2M	15.12%	-18.85%	-4.35	2.06	24.65%	80.36%
TXMD	25.8M	1.3M	18.52%	-47.17%	-3.49	19.84	-98.14%	-104.71%
ACRX	18.4M	89.6M	6.93%	25.60%	-1.29	0.19	287.27%	-129.41%
AGRX	2.5M	21.5M	2.70%	-90.89%	-0.32	0.12	66.16%	61.83%
ACOR	633.5K	115.7M	-50.00%	-97.38%	0	0.01	-2.22%	-352.48%

Agile Therapeutics Inc News

Latest updates

Agile Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)														(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Revenue	58.1%	5,716,000	3,614,500	6,662,000	5,503,000	3,813,000	3,995,500	3,002,000	2,126,000	1,761,000	1,513,500	1,287,000	1,185,000	116,000	749,000
Cost Of Revenue	-23.3%	1,680,000	2,191,000	2,477,000	2,307,000	2,003,000	1,653,000	1,425,000	2,231,000	1,527,000	5,701,000	2,711,000	1,145,000	1,161,000	-
Gross Profit	183.5%	4,036,000	1,423,500	4,185,000	3,196,000	1,810,000	2,342,500	1,577,000	-105,000	234,000	-4,187,500	-1,424,000	40,000	-1,045,000	467,000
Operating Expenses	24.1%	6,793,000	5,474,500	8,185,000	8,322,000	8,518,000	9,220,000	20,285,000	11,293,000	15,807,000	18,170,500	14,350,000	16,691,000	15,177,000	17,208,000
S&GA Expenses	-1.3%	3,682,000	3,729,000	4,800,000	4,570,000	4,670,000	6,845,500	5,560,000	7,411,000	10,553,000	13,004,500	9,386,000	11,977,000	9,253,000	10,669,500
R&D Expenses	816.7%	495,000	54,000	705,000	703,000	763,000	352,000	788,000	856,000	1,257,000	1,673,000	1,593,000	862,000	2,123,000	3,012,000
EBITDA Margin	54.3%	-0.30	-0.66	-0.61	-1.02	-1.31	-2.36	-4.79	-7.59	-10.97	-15.87	-19.09	-25.49	-35.27	-
Interest Expenses	-39.2%	185,000	304,500	341,000	372,000	402,000	432,000	1,004,000	823,000	872,000	1,000,000	999,000	993,000	922,000	904,000
Income Taxes	-	-	-	-	-	-	-	-	-	-4,675,000	-	-	-	-	-
Earnings Before Taxes	128.7%	1,284,000	-4,468,500	-799,000	-3,809,000	-5,390,000	-3,930,000	-5,930,000	-5,168,000	-15,060,000	-19,530,000	-16,772,000	-17,637,000	-17,128,000	-17,620,000
EBT Margin	50.9%	-0.36	-0.74	-0.70	-1.17	-1.58	-2.76	-5.44	-8.45	-12.01	-17.33	-20.72	-27.45	-37.91	-
Net Income	128.7%	1,284,000	-4,469,000	-799,000	-3,809,000	-5,389,000	-3,930,000	-5,930,000	-5,168,000	-10,385,000	-19,530,000	-16,772,000	-17,637,000	-17,128,000	-17,620,000
Net Income Margin	50.9%	-0.36	-0.74	-0.70	-1.17	-1.58	-2.33	-4.88	-7.75	-11.19	-17.33	-20.72	-27.45	-37.91	-
Free Cashflow	-1539.5%	-2,476,000	172,000	365,000	-8,519,000	-1,595,000	-1,559,000	-16,703,000	-2,941,000	-14,877,000	-16,673,000	-18,645,000	-15,414,000	-14,739,000	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	23.0%	13.00	10.00	11.00	13.00	14.00	14.00	18.00	33.00	29.00	39.00	37.00	52.00	59.00	73.00	89.00	103	109	50.00	34.00	25.00	26.00
Current Assets	25.8%	12.00	10.00	10.00	12.00	11.00	11.00	15.00	18.00	14.00	24.00	22.00	37.00	44.00	57.00	73.00	89.00	95.00	35.00	20.00	11.00	12.00
Cash Equivalents	2.3%	3.00	3.00	3.00	3.00	4.00	5.00	6.00	13.00	4.00	19.00	15.00	26.00	16.00	14.00	24.00	39.00	94.00	34.00	18.00	11.00	12.00
Inventory	36.9%	4.00	3.00	2.00	3.00	2.00	1.00	2.00	2.00	3.00	1.00	3.00	3.00	2.00	-	-	-	-	-	-	-	-
Net PPE	-33.3%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	12.00	12.00	12.00	13.00	13.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00
Liabilities	-13.7%	23.00	27.00	23.00	25.00	23.00	20.00	21.00	30.00	35.00	35.00	26.00	28.00	24.00	24.00	23.00	22.00	18.00	4.00	3.00	3.00	3.00
Current Liabilities	3.2%	21.00	21.00	18.00	15.00	19.00	13.00	12.00	29.00	26.00	29.00	10.00	12.00	9.00	7.00	7.00	6.00	3.00	4.00	2.00	2.00	1.00
Long Term Debt	-100.0%	-	2.00	-	-	-	1.00	-	-	-	-	16.00	16.00	16.00	16.00	16.00	16.00	15.00	-	-	-	-
LT Debt, Current	-100.0%	-	2.00	2.00	2.00	2.00	1.00	1.00	13.00	12.00	17.00	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	36.7%	-10.32	-16.32	-	-	-9.43	-5.54	6.00	2.00	3.00	4.00	11.00	25.00	35.00	49.00	66.00	81.00	91.00	46.00	0.00	273	271
Retained Earnings	0.3%	-421	-423	-418	-417	-414	-408	-404	-398	-393	-383	-363	-346	-329	-312	-295	-279	-268	-260	-254	-249	-246
Additional Paid-In Capital	1.2%	412	407	406	406	405	403	402	401	388	387	374	372	364	362	361	360	359	306	286	273	271
Accumulated Depreciation	-100.0%	-	0.00	-	-	-	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	131.3%	7.00	3.00	2.00	2.00	47.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	5.00	-	-	-	14.00	-	-	-	101	-	-	-	197	-	-	-	52.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-1539.5%	-2,476	172	365	-8,519	-1,595	-1,559	-16,703	-2,934	-14,751	-16,618	-18,580	-15,336	-14,668	-17,342	-15,320	-6,765	-7,884	-3,270	-5,080	-2,378	-4,961
Share Based Compensation	-40.9%	333	563	439	481	498	524	536	669	764	866	887	843	742	711	647	839	621	415	378	479	490
Cashflow From Investing	-	-	-	-	-	-	-	-	-7.00	-126	-55.00	4,935	18,395	16,185	7,527	-173	-47,880	-164	-68.00	-	-	-
Cashflow From Financing	620.5%	2,535	-487	-278	6,875	778	660	9,821	12,225	-523	21,081	2,262	6,595	484	115	210	166	67,494	19,447	12,894	1,404	8,670

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AGRX Income Statement

2024-03-31

Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statements of Operations and Comprehensive Income (Loss)
Revenues, net	$ 5,716	$ 3,813
Cost of product revenues	1,680	2,003
Gross profit	4,036	1,810
Operating expenses:
Research and development	495	763
Selling and marketing	3,682	4,670
General and administrative	2,616	3,085
Total operating expenses	6,793	8,518
Loss from operations	(2,757)	(6,708)
Other income (expense)
Interest income	23	33
Interest expense	(185)	(402)
Unrealized gain on warrant liability	4,203	1,687
Total other income (expense), net	4,041	1,318
Income (loss) before benefit from income taxes	1,284	(5,390)
Net income (loss) and comprehensive income (loss)	$ 1,284	$ (5,390)
Net income (loss) per share (basic) (in dollars per share)	$ 0.28	$ (5.91)
Net income (loss) per share (diluted) (in dollars per share)	$ 0.28	$ (5.91)
Weighted-average common shares (basic) (in shares)	4,631,902	912,044
Weighted-average common shares (diluted) (in shares)	4,631,902	912,044

AGRX Balance Sheet

2024-03-31

Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 2,615	$ 2,557
Accounts receivable, net	4,813	3,392
Inventory, net	3,748	2,738
Prepaid expenses and other current assets	811	843
Total current assets	11,987	9,530
Property and equipment, net	50	75
Right of use asset	335	412
Other non-current assets	238	238
Total assets	12,610	10,255
Current liabilities:
Long-term debt, current portion		1,515
Notes payable, current portion		191
Accounts payable	12,620	9,574
Accrued expenses	8,443	9,131
Lease liability, current portion	378	366
Total current liabilities	21,441	20,777
Lease liabilities, long-term		100
Warrant liability	1,493	5,696
Total liabilities	22,934	26,573
Commitments and contingencies (Note 9)
Stockholders' deficit
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 4,850 issued and no shares outstanding at March 31, 2024 and no shares issued and outstanding at December 31, 2023
Common stock, $0.0001 par value, 300,000,000 shares authorized, 6,856,229 and 2,963,657 issued and outstanding at March 31, 2024 and December 31, 2023, respectively	5	4
Additional paid-in capital	411,555	406,846
Accumulated deficit	(421,884)	(423,168)
Total stockholders' deficit	(10,324)	(16,318)
Total liabilities and stockholders' deficit	$ 12,610	$ 10,255

About Agile Therapeutics Inc

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.

CEO	Mr. Alfred F. Altomari
WEBSITE	agiletherapeutics.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	22

Agile Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Agile Therapeutics Inc? What does AGRX stand for in stocks?

AGRX is the stock ticker symbol of Agile Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Agile Therapeutics Inc (AGRX)?

As of Fri May 17 2024, market cap of Agile Therapeutics Inc is 2.48 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AGRX stock?

You can check AGRX's fair value in chart for subscribers.

What is the fair value of AGRX stock?

You can check AGRX's fair value in chart for subscribers. The fair value of Agile Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Agile Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AGRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Agile Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether AGRX is over valued or under valued. Whether Agile Therapeutics Inc is cheap or expensive depends on the assumptions which impact Agile Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AGRX.

What is Agile Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, AGRX's PE ratio (Price to Earnings) is -0.32 and Price to Sales (PS) ratio is 0.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AGRX PE ratio will change depending on the future growth rate expectations of investors.